HC Wainwright reaffirmed their buy rating on shares of Verastem (NASDAQ:VSTM – Free Report) in a report released on Friday, Benzinga reports. They currently have a $7.00 price target on the biopharmaceutical company’s stock.
Other equities analysts have also recently issued reports about the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Verastem in a research note on Friday. Guggenheim initiated coverage on Verastem in a research report on Monday, September 30th. They set a “buy” rating and a $13.00 target price for the company. StockNews.com upgraded Verastem from a “sell” rating to a “hold” rating in a report on Monday, August 12th. Truist Financial decreased their price target on Verastem from $18.00 to $15.00 and set a “buy” rating for the company in a research note on Tuesday, August 13th. Finally, Royal Bank of Canada cut their price objective on Verastem from $16.00 to $13.00 and set an “outperform” rating on the stock in a research report on Friday, August 9th. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $14.57.
Read Our Latest Analysis on VSTM
Verastem Price Performance
Verastem (NASDAQ:VSTM – Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.31) EPS for the quarter, topping the consensus estimate of ($1.06) by $0.75. The firm had revenue of $10.00 million for the quarter. Equities analysts expect that Verastem will post -3.36 EPS for the current year.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Nantahala Capital Management LLC purchased a new stake in shares of Verastem in the 2nd quarter worth $1,192,000. Bank of New York Mellon Corp purchased a new position in shares of Verastem during the second quarter valued at $203,000. Rhumbline Advisers raised its holdings in shares of Verastem by 4,172.0% in the second quarter. Rhumbline Advisers now owns 28,793 shares of the biopharmaceutical company’s stock valued at $86,000 after acquiring an additional 28,119 shares in the last quarter. Acadian Asset Management LLC purchased a new stake in Verastem in the second quarter worth about $82,000. Finally, SG Americas Securities LLC bought a new position in Verastem during the 3rd quarter worth about $43,000. Institutional investors own 88.37% of the company’s stock.
About Verastem
Verastem, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors.
Read More
- Five stocks we like better than Verastem
- 3 Warren Buffett Stocks to Buy Now
- Misses and Beats: 3 Stocks That Are Moving Markets Right Now
- How to Buy Cheap Stocks Step by Step
- Cisco on the Rise: AI Potential and Analyst Upgrades Drive Gains
- CD Calculator: Certificate of Deposit Calculator
- MarketBeat Week in Review – 10/14 – 10/18
Receive News & Ratings for Verastem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verastem and related companies with MarketBeat.com's FREE daily email newsletter.